Xing B, Yu J, Zhang H, Li Y
A., Kain, T
Multiple cardiovascular outcome trials (ELIXAlixisenatide, LEADERliraglutide, SUSTAIN-6semaglutide, EXSCELexenatide, Harmony Outcomesalbiglutide, REWINDdulaglutide, and PIONEER-6oral semaglutide) have reported, to a greater or lesser extent, improvements in cardiovascular outcomes, with a systematic review and meta-analysis of these trials involving a combined total of 56,004 participants showing that these drugs as a class reduced major adverse cardiovascular events by 12%, death from cardiovascular causes by 12%, fatal or nonfatal stroke by 16%, and fatal or nonfatal myocardial infarction by 9%
What if the missing piece in weight loss wasnt willpower, but the right mix of science, structure, and support
If GLP-1 medications caused C-cell stimulation in humans like they do in rats, calcitonin levels would rise during treatment